News 25 Mar 2026 GluGene Therapeutics: Democratizing Gene Therapy with Precision-Guided AAV Technology "While the majority of FDA-approved gene therapies utilize AAV (Adeno-Associated Virus), these vectors often migrate to non-target tissues, necessitating high-dose… GluGene
News 10 Mar 2026 Donor Interview: Professor Jae-Hyung Jang, Department of Chemical and Biomolecular Engineering (CTO of GluGene Therapeutics) 1. Could you please provide a brief self-introduction for the Yonseians and subscribers reading this article? I am Jae-Hyung Jang,… GluGene
